KRIT1 sirna

KRIT1 siRNA (Mouse)

Cat. Num. AAA8237787

• Gene Names: Krit1; Ccm1; AA432855; AI450393; AI643869; BB155247; BB235701; 2010007K12Rik; A630036P20Rik
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: KRIT1; KRIT1 siRNA (Mouse); CCM1; Krev interaction trapped protein 1; Krev interaction trapped 1; Cerebral cavernous malformations 1 protein homolog; KRIT1 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: KRIT1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 329

• Applicable Applications for KRIT1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse KRIT1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for KRIT1 sirna

siRNA to inhibit KRIT1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 282847448
• NCBI GeneID: 79264
• NCBI Accession #: NP_001164023.1
• NCBI GenBank Nucleotide #: NM_001170552.1
• UniProt Accession #: Q6S5J6; Q6VSV2; Q7TPR8; Q8C9Q6; Q9EPY2; Q9ERH0
• Molecular Weight: 37,297 Da
• NCBI Official Full Name: krev interaction trapped protein 1 isoform 2
• NCBI Official Synonym Full Names: KRIT1, ankyrin repeat containing
• NCBI Official Symbol: Krit1
• NCBI Official Synonym Symbols: Ccm1; AA432855; AI450393; AI643869; BB155247; BB235701; 2010007K12Rik; A630036P20Rik
• NCBI Protein Information: krev interaction trapped protein 1
• UniProt Protein Name: Krev interaction trapped protein 1
• Protein Family: Krev interaction trapped protein
• UniProt Gene Name: Krit1
• UniProt Synonym Gene Names: Ccm1; Krev interaction trapped 1
• UniProt Entry Name: KRIT1_MOUSE

Uniprot Description

KRIT1: Component of the CCM signaling pathway which is a crucial regulator of heart and vessel formation and integrity. Negative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits EKR1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction, and cell junction stabilization. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin-D1 (CCND1) levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels. Defects in KRIT1 are the cause of cerebral cavernous malformations type 1 (CCM1). Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and usually present clinically during the 3rd to 5th decade of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Motility/polarity/chemotaxis; G protein regulator, misc.

Cellular Component: extracellular space; microtubule; protein complex; cytoskeleton; membrane; cell; cytoplasm; plasma membrane; intercellular junction; cell junction

Molecular Function: protein binding; phosphatidylinositol-4,5-bisphosphate binding; microtubule binding; protein complex binding; GTPase regulator activity

Biological Process: negative regulation of angiogenesis; positive regulation of protein binding; regulation of catalytic activity; cell redox homeostasis; negative regulation of endothelial cell proliferation; angiogenesis